Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2018 · 10-K
Revenue$758.00K$758.00K−19.8% vs Q4 2017 Net Income-$44.95M-$44.95MN/M vs Q4 2017 EPS, diluted—
Gross Profitderived$706,000−25.3% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income
Operating Cash Flowderived-$5,812,000N/M Free Cash Flowderived-$5,969,000N/M Margins · derivedGross margin93.1%−6.9 pt vs Q4 2017
Operating margin-1333.4%−321.4 pt vs Q4 2017
Net margin-5930.3%+1681.7 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 14, 2019 · 73 d after period end